Publications:

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas.

Blood

Heward, James J; Konali, Lola L; D'Avola, Annalisa A; Close, Karina K; Yeomans, Alison A; Philpott, Martin M; Dunford, James J; Rahim, Tahrima T; Al Seraihi, Ahad F AF; Wang, Jun J; Korfi, Koorosh K; Araf, Shamzah S; Iqbal, Sameena S; Bewicke-Copley, Findlay F; Kumar, Emil E; Barisic, Darko D; Calaminici, Maria M; Clear, Andrew A; Gribben, John J; Johnson, Peter P; Neve, Richard R; Cutillas, Pedro P; Okosun, Jessica J; Oppermann, Udo U; Melnick, Ari A; Packham, Graham G; Fitzgibbon, Jude J

Publication Date: 2021-08-05

Variant appearance in text: KMT2D: P648Tfs*2

PubMed Link: 33786580

Variant Present in the following documents:

• Main text

View BVdb publication page

Phase and context shape the function of composite oncogenic mutations.

Nature

Gorelick, Alexander N AN; Sánchez-Rivera, Francisco J FJ; Cai, Yanyan Y; Bielski, Craig M CM; Biederstedt, Evan E; Jonsson, Philip P; Richards, Allison L AL; Vasan, Neil N; Penson, Alexander V AV; Friedman, Noah D ND; Ho, Yu-Jui YJ; Baslan, Timour T; Bandlamudi, Chaitanya C; Scaltriti, Maurizio M; Schultz, Nikolaus N; Lowe, Scott W SW; Reznik, Ed E; Taylor, Barry S BS

Publication Date: 2020-06

Variant appearance in text: KMT2D: P648Tfs*2

PubMed Link: 32461694

Variant Present in the following documents:

• NIHMS1582596-supplement-1582596_Supp_Tab1-5.xlsx, sheet 2

View BVdb publication page